MAPT and dementia: In light of patients’ clinical profile ascertained along 2-year follow-up, and after FGD-PET completion and the acquisition of the complete CSF profile (including the assessment of Abeta 1–42, total tau, and phospho-tau proteins), the dementia group was subdivided into: AD-type (n = 26) and frontotemporal dementia (FTD) (n = 14; see Table 2).